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Abstract: Patients undergoing laparoscopic gynecologic surgery and receiving postoperative analgesia
with opioids have a high risk of postoperative nausea and vomiting (PONV). We compared the
antiemetic efficacy of three doses of ramosetron in this high-risk population. In this prospective,
double-blind trial, 174 patients randomly received ramosetron 0.3 mg (R0.3 group; n = 58), 0.45 mg
(R0.45 group; n = 58), or 0.6 mg (R0.6 group; n = 58) at the end of surgery. The primary outcome
was the incidence of PONV during the first postoperative 48 h. Nausea severity, pain scores, adverse
events, and patient satisfaction (1–4; 4, excellent) were assessed. The incidence of PONV was not
different between groups (35%, 38%, and 35% in R0.3, R0.45, and R0.6 groups; p = 0.905). Nausea
severity, pain scores, and incidence of adverse events (dizziness, headache, or sedation) were similar
between groups. Compared to the R0.3 group, the R0.45 and R0.6 groups had lower incidence
of premature discontinuation of fentanyl-based patient-controlled analgesia primarily because of
intractable PONV (9% and 5% vs. 24%; p = 0.038), and higher satisfaction scores (3.4 ± 0.8 and
3.3 ± 0.7 vs. 2.4 ± 0.9; p = 0.005). Compared to ramosetron 0.3 mg, ramosetron 0.45 and 0.6 mg did not
reduce PONV, but reduced premature discontinuation of patient-controlled analgesia and increased
patient satisfaction, without increasing adverse events.
Keywords: 5-hydroxytryptamine type 3 receptor antagonist; gynecologic laparoscopy; postoperative
nausea and vomiting; ramosetron
1. Introduction
Postoperative nausea and vomiting (PONV) is a distressing and common complication of
general anesthesia and surgery. Patients undergoing laparoscopic gynecologic surgery and receiving
opioid-based patient-controlled analgesia (PCA) after surgery may be at high risk of PONV because of
patient and surgical factors [1,2]. The incidence of PONV may be as high as 80% in high-risk patients [3].
Although numerous strategies involving the use of different pharmacological classes (including
anticholinergics, antihistamines, phenothiazines, and butyrophenones) have been employed to prevent
PONV [4], no approach is universally successful. Currently, 5-hydroxytryptamine (5-HT3) receptor
antagonists are recommended as first- and second-line pharmacologic antiemetic agents for PONV
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prophylaxis because of their efficacy and limited side effects [5]. Ramosetron is the most recently
developed selective 5-HT3 receptor antagonist, and is more effective than other 5-HT3 receptor
antagonists because of its higher receptor binding capacity and longer half-life [6].
The efficacy of ramosetron 0.3 mg has been established in chemotherapy-induced emesis, and this
dose has also been recommended for the prevention of PONV [7,8]. However, the optimal dose of
ramosetron has not yet been established in high-risk surgical patients. Although several dose-ranging
studies of ramosetron for PONV prophylaxis have been conducted, some did not stratify patients according
to surgery- and patient-specific risk levels for PONV [9,10] and others were found to be fabricated and
subsequently retracted [11,12]. In addition, little is known about the effective and safe dose of ramosetron
that does not produce undesirable adverse effects, such as headache, dizziness, or drowsiness.
We therefore conducted a prospective, randomized, double-blind trial to determine the most
appropriate dose of ramosetron for preventing PONV in high-risk patients undergoing laparoscopic
gynecologic surgery and receiving opioid-based PCA after surgery.
2. Materials and Methods
2.1. Study Design and Patients
This prospective, randomized, double-blind study was approved by the institutional review board
and hospital research ethics committee of Severance Hospital, Yonsei University Health System, Seoul,
South Korea, on 9 February 2015 (#4-2014-1065). It was registered at ClinicalTrials.gov on 17 December
2015 (NCT02478645). Written informed consent was obtained from all participants. Women between
20 and 70 years of age who underwent elective laparoscopic gynecologic surgery from June 2015 to
February 2016 were included. All patients were American Society of Anesthesiologists’ (ASA) physical
status class I to III. The exclusion criteria were a body mass index > 35 kg·m−2, vomiting or receipt
of antiemetics or systemic steroids within 24 h before surgery, vestibular dysfunction symptoms, or
an allergy to any study drug. Known risk factors for PONV were assessed using the simplified risk
scoring system of Apfel et al. [2].
2.2. Randomization and Blinding
Using a computer-generated random table, enrolled patients were randomized in a 1:1 ratio to
receive 1 of 3 doses of intravenous (IV) ramosetron, regardless of body weight. The doses were 0.3 mg
(group R0.3), 0.45 mg (group R0.45), or 0.6 mg (group R0.6). Group assignments were concealed in
sealed envelopes. The surgeons, patients, and investigators collecting postoperative data were blind to
the group assignment. The anesthesia team and nurses in the post-anesthesia care unit (PACU) and
hospital ward were also blind to the group assignment.
2.3. Patient Management
Patients fasted before surgery according to local guidelines (at least 8 h for solid foods and
2 h for clear fluids) and received no premedication. Routine ASA monitoring was applied in the
operating theater. General anesthesia was induced with propofol 1.5 to 2.5 mg·kg−1 and remifentanil
1 µg·kg−1, and tracheal intubation was facilitated with rocuronium 0.8 mg·kg−1. Anesthesia was
maintained with desflurane 5% to 8% in an oxygen-air mixture (FiO2 = 0.5) and remifentanil infusion
at 0.05 to 0.1 µg·kg−1·min−1. The desflurane and remifentanil were titrated to maintain the mean
blood pressure and heart rate within 25% of baseline values and bispectral index in the range of 40 to
60. At the end of surgery, neuromuscular blockade was reversed with neostigmine 20 µg·kg−1 and
glycopyrrolate 4 µg·kg−1. After emergence from anesthesia, patients received an IV bolus of fentanyl
50 µg for pain control, as well as a single dose of ramosetron (according to group assignment) for PONV
prophylaxis. IV-PCA with fentanyl was begun 30 min before the end of surgery for postoperative
analgesia. The settings were as follows: basal infusion rate of 0.3 µg·kg−1·h−1, on-demand 0.15-µg·kg−1
boluses, and lockout interval of 15 min. Ondansetron 8 mg was added to the IV-PCA solution (total
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100 mL). In addition to this fentanyl-based PCA, all patients received IV ketorolac 30 mg every 8 h for
the first 24 h after surgery.
2.4. Assessments and Outcome Measures
Postoperatively, the incidence and severity of nausea were assessed during two time periods: 0 to
6 h and 6 to 48 h after surgery. The severity of nausea was evaluated on a five-point numerical rating
scale (NRS; 1 = none, 2 = mild, 3 = moderate, 4 = severe, or 5 = intractable). If a patient developed more
than moderate nausea or emesis or required an antiemetic, IV metoclopramide 10 mg was administered
as a rescue antiemetic. The IV-PCA was halted if severe nausea persisted despite receipt of a rescue
antiemetic and/or at the patient’s request. After re-evaluating the nausea level 2 h after IV-PCA was
halted, a decision was made to either resume or discontinue the IV-PCA. The number of patients for
whom IV-PCA was halted or discontinued was recorded. The level of pain was assessed on an 11-point
NRS (0 = no pain to 10 = worst imaginable pain). Patients with breakthrough pain during IV-PCA
received additional analgesics upon request or when they reported a pain score ≥ 4. These analgesics
consisted of IV fentanyl 50 µg in the PACU and intramuscular (IM) tramadol 50 mg on the hospital
ward. Intermittent IM tramadol 50 mg was also administered for breakthrough pain during premature
halting or discontinuation of the IV-PCA. We recorded the pain score at 6 h and 48 h after surgery,
as well as the worst pain score during 0 to 6 h and 6 to 48 h after surgery. The occurrence of the most
common 5-HT3 antagonist side effects—headache, dizziness, and drowsiness—was also recorded.
At 48 h after surgery, the patients were asked to rate their overall level of satisfaction regarding
analgesia and control of PONV on a four-point scale (1 = poor, 2 = fair, 3 = good, or 4 = excellent).
The primary outcome measure of this study was the incidence of PONV during the first 48 h
postoperatively. Secondary outcome measures included the severity of nausea, need for rescue
antiemetics, pain scores, additional analgesic requirements, adverse events, early discontinuation of
PCA, and patient satisfaction.
2.5. Statistical Analysis
Sample size was calculated based on the previously reported 70% incidence of PONV after
prophylaxis with ramosetron 0.3 mg in patients undergoing laparoscopic gynecologic surgery [13].
Prior reports defined effective prevention of PONV as a 30% reduction in the incidence of PONV [14].
We therefore estimated that a total of 159 patients would be required to detect a 30% reduction in
PONV from a basal incidence of 70%, with 90% power at a significance of p < 0.05. We factored in a
10% dropout rate and thereby enrolled 59 patients in each group.
All statistical analyses were performed using SPSS 25.0 (SPSSFW, SPSS Inc., IBM, Armonk, NY, USA)
software. After performing the Kolmogorov–Smirnov test for normality of distribution, continuous
variables between groups were compared using one-way analysis of variance or Kruskal–Wallis test
and expressed as mean ± standard deviation or median (interquartile range). If a statistical difference
was noted in multiple comparisons between groups, the p-value was adjusted by Bonferroni correction.
Dichotomous variables were compared using chi-square or Fisher’s exact tests and expressed as an
absolute number (percentage). A p-value < 0.05 was considered statistically significant.
3. Results
3.1. Patients
A total of 177 patients were enrolled and randomized. One patient in the R0.3 group and one
patient in the R0.45 group withdrew from the study after randomization because of personal reasons.
One patient in the R0.6 group had a large myoma and was excluded from the study when the surgery
was converted to an open procedure. Data were analyzed from the remaining 174 patients (58 in
each group) (Figure 1). Patient characteristics, including PONV risk factors and operative data, were
comparable between the three groups (Table 1).
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Table 1. Patient characteristics. 
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R0.6 Group  
(n = 58) 
p-Value 
Age (years) 42.2 (22–64) 41.0 (21–62) 41.2 (20–70) 0.809 
Body mass index (kg/m2) 23.9 ± 4.2 22.9 ± 3.5 22.8 ± 3.4 0.178 
ASA classification (I/II/III) 52/4/2 49/6/3 50/8/2 0.774 
Motion sickness (n) 14 (24%) 15 (26%) 14 (24%) 0.970 
Previous PONV (n) 2 (3%) 3 (5%) 0 0.237 
Non-smoker (n) 56 (97%) 56 (97%) 56 (97%) >0.999 
Apfel’s score     
2 (n) 2 (3%) 2 (3%) 2 (3%) 
0.996 3 (n) 41 (71%) 40 (69%) 42 (72%) 
4 (n) 15 (26%) 16 (28%) 14 (25%) 
Operation duration (min) 69.0 (52.0, 100.5) 69.0 (40.0, 104.8) 77.0 (58.5, 111.80) 0.221 
Anesthesia duration (min) 95.0 (75.0, 131.3) 95.0 (69.8, 132.5) 100.0 (80.0, 140.0) 0.239 
Type of surgery      
Salpingo-oophorectomy 18 15 10 
0.585 Ovarian cyst enuclation 15 22 20 
Myomectomy 9 7 10 
Hysterectomy 16 14 18 
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Table 1. Patient characteristics.
R0.3 Group
(n = 58)
R0.45 Group
(n = 58)
R0.6 Group
(n = 58) p-Value
Age (years) 42.2 (22–64) 41.0 (21–62) 41.2 (20–70) 0.809
Body mass index (kg/m2) 23.9 ± 4.2 22.9 ± 3.5 22.8 ± 3.4 0.178
ASA classification (I/II/III) 52/4/2 49/6/3 50/8/2 0.774
Motion sickness (n) 14 (24%) 15 (2 %) 14 (24%) 9 0
Previous PONV (n) 2 (3%) 3 (5%) 0 0.237
Non-smoker (n) 56 (97%) 56 (97%) 56 (97%) >0.999
Apfel’s score
2 (n) 2 (3%) 2 (3%) 2 (3%)
0.9963 (n) 41 (71%) 40 (69%) 42 (72%)
4 (n) 15 (26%) 16 (28 14 25%)
Operation duration (min) 69.0 (52.0, 100.5) 69.0 (40.0, 104.8) 77.0 (58.5, 111.80) 0.221
Anesthesia duration (min) 95.0 (75.0, 131.3) 95.0 (69.8, 132.5) 100.0 (80.0, 140.0) 0.239
Type of surgery
Salpingo-oophorectomy 18 15 10
0.585
Ovarian cyst enuclation 15 22 20
Myom ctomy 9 7 10
Hysterectomy 16 14 18
Values are mean (ranges), mean ± standard deviation, number (%), or median (IQR). PONV, postoperative nausea
and vomiting; R0.3 group, ramosetron 0.3 mg group; R0.45 group, ramosetron 0.45 mg group; R0.6 group, ramosetron
0.6 mg group; ASA classification, American Society of Anesthesiologists’ physical status classification.
J. Clin. Med. 2019, 8, 2188 5 of 10
3.2. Postoperative Nausea and Vomiting
The incidence of PONV during the first 48 h after surgery was not statistically different between
the three groups (p = 0.905): 20 patients (35%) in the R0.3 group, 22 patients (38%) in the R0.45 group,
and 20 patients (35%) in the R0.6 group. There were also no significant differences in incidence or
severity of nausea, incidence of emesis, or number of patients requiring rescue antiemetics during the
first 6 h and 6 to 48 h after surgery between the three groups (p > 0.05 for all comparisons) (Table 2).
Table 2. Incidence of nausea and vomiting, and use of rescue antiemetics.
R0.3 Group
(n = 58)
R0.45 Group
(n = 58)
R0.6 Group
(n = 58) p-Value
Incidence of nausea
Early period (the first 6 h after surgery) 12 (21%) 11 (19%) 12 (21%) 0.965
Late period (6 to 48 h after surgery) 16 (28%) 15 (26%) 14 (24%) 0.914
Overall 20 (35%) 22 (38%) 20 (35%) 0.905
Severity of nausea
Early period (the first 6 h after surgery)
(none/mild/moderate/severe/intractable) 46/0/9/2/1 47/1/8/2/0 46/4/7/1/0 0.447
Late period (6 to 48 h after surgery)
(none/mild/moderate/severe/intractable) 42/4/4/8/0 43/0/8/7/0 44/1/10/3/0 0.119
Overall 38/2/9/8/1 36/1/12/9/0 38/3/13/4/0 0.666
Emesis
Early period (the first 6 h after surgery) 1 (2%) 2 (3.4%) 3 (5.2%) 0.596
Late period (6 to 48 h after surgery) 0 1 (2%) 2 (3.4%) 0.361
Overall 1 (1.7%) 3 (5.2%) 5 (8.6%) 0.245
PONV
Early period (the first 6 h after surgery) 12 (21%) 11 (19%) 12 (21%) 0.965
Late period (6 to 48 h after surgery) 16 (28%) 15 (26%) 14 (24%) 0.914
Overall 20 (35%) 22 (38%) 20 (35%) 0.905
Patients requiring additional antiemetics
Early period (the first 6 h after surgery) 11 (19%) 10 (17%) 8 (14%) 0.749
Late period (6 to 48 h after surgery) 6 (10%) 13 (22%) 11 (19%) 0.208
Overall 16 (28%) 21 (36%) 16 (28%) 0.507
Values are number (%). PONV, postoperative nausea and vomiting; R0.3 group, ramosetron 0.3 mg group; R0.45
group, ramosetron 0.45 mg group; R0.6 group, ramosetron 0.6 mg group.
3.3. Postoperative Pain
Postoperative pain scores at 6 h and 48 h after surgery, as well as the worst pain scores during
the first 6 h and 6 to 48 h after surgery, were not statistically different between groups. Likewise,
the number of patients requiring rescue analgesics was similar between groups (Table 3).
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Table 3. Postoperative pain score and use of rescue analgesics.
R0.3 Group
(n = 58)
R0.45 Group
(n = 58)
R0.6 Group
(n = 58) p-Value
Pain score
Early period (at 6 h after surgery) 3 (2, 3) 3 (3, 3) 3 (2, 3) 0.229
Late period (at 48 h after surgery) 2 (2, 3) 2 (2, 3) 2 (2, 2) 0.135
Worst pain score
Early period (the first 6 h after surgery) 5 (4, 6) 5 (4, 6) 5 (4, 6) 0.879
Late period (6 to 48 h after surgery) 3 (2, 5) 3 (2, 4) 3 (2, 3) 0.374
Patients requiring additional analgesics
Early period (the first 6 h after surgery) 21 (36%) 17 (29%) 17 (29%) 0.654
Late period (6 to 48 h after surgery) 15 (26%) 14 (24%) 8 (14%) 0.229
Values are mean ± standard deviation or number (%). Pain scores were assessed using an 11-point numerical rating
scale (0, no pain, to 10, worst imaginable pain). R0.3 group, ramosetron 0.3 mg group; R0.45 group, ramosetron 0.45
mg group; R0.6 group, ramosetron 0.6 mg group.
3.4. Adverse Events, Premature Discontinuation of IV-PCA, and Patient Satisfaction
The most frequent adverse events were dizziness and headache. There were no statistically
significant differences in the incidence of dizziness (p = 0.806) or headache between groups (p = 0.545).
No patient in any group had excessive sedation (Table 4).
Table 4. Adverse events.
R0.3 Group
(n = 58)
R0.45 Group
(n = 58)
R0.6 Group
(n = 58) p-Value
Dizziness 16 (28%) 14 (24%) 13 (22%) 0.806
Headache 10 (17%) 6 (10%) 9 (16%) 0.545
Drowsiness 0 0 0 -
Values are number (%). R0.3 group, ramosetron 0.3 mg group; R0.45 group, ramosetron 0.45 mg group; R0.6 group,
ramosetron 0.6 mg group.
The proportion of patients requiring premature discontinuation of IV-PCA was lower in the R0.45
(five patients (9%)) and R0.6 (three patients (5%)) groups than in the R0.3 group (14 patients (24%))
(p = 0.005). In the R0.3 group, the reasons for IV-PCA discontinuation were nausea in seven patients,
nausea and dizziness in four patients, dizziness in two patients, and headache and dizziness in one
patient; in the R0.45 group, the reasons were nausea in four patients and nausea and dizziness in one
patient; and in the R0.6 group, the reason was nausea in three patients (Table 4). Patient satisfaction
scores regarding control of PONV and analgesia were significantly higher in the R0.45 (3.4 ± 0.8) and
R0.6 (3.3 ± 0.7) groups than in the R0.3 group (2.4 ± 0.9) (p = 0.005).
4. Discussion
In patients undergoing laparoscopic gynecologic surgery and receiving opioid-based analgesia
after surgery, ramosetron 0.45 and 0.6 mg did not reduce PONV during the first 48 h postoperatively,
when compared to ramosetron 0.3 mg. However, ramosetron 0.45 and 0.6 mg decreased the incidence
of premature discontinuation of IV-PCA and increased patient satisfaction.
Among 5-HT3 antagonists, ramosetron has the highest receptor affinity and longest plasma
half-life and therefore is the most potent and longest acting [6]. Clinically, ramosetron is more effective
for reducing PONV than granisetron [15] or ondansetron [16,17]. In a meta-analysis, ramosetron 0.3
mg was consistently beneficial for preventing PONV (relative risk 0.4, 95% confidence interval (CI)
0.3–0.6), when compared to placebo, and it was also safe, producing no serious adverse events [18].
However, despite prophylaxis with ramosetron, PONV has still been reported in more than 30% of
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patients [15,17]. The recommended dose of ramosetron for PONV prophylaxis is 0.3 mg, which is the
same as for chemotherapy-induced nausea and vomiting, and little is known about the effective and
safe dose in high-risk perioperative patients.
The etiology of PONV is multifactorial. Among patient-specific predictors, female sex, previous
motion sickness and/or PONV, non-smoking status, and postoperative opioid use have been identified
as significant risk factors for PONV (these are the Apfel PONV risk factors) [2]. The type of surgery
also significantly influences the occurrence of PONV, with gynecologic (odds ratio (OR) 1.24, 95% CI
1.02–1.52) and laparoscopic (OR 1.37, 95% CI 1.07–1.77) surgery being associated with a higher incidence
of PONV, when compared with general surgery [1]. The risk of PONV increased more in patients
undergoing both laparoscopic and gynecologic surgeries [19], and up to 66.7% of patients undergoing
laparoscopic gynecologic surgery still experienced PONV despite prophylaxis with ondansetron [14].
Ramosetron 0.3 mg showed similar efficacy to ondansetron 8 mg in reducing the incidence of PONV
during the first 24 h after gynecologic surgery [8].
Several dose-ranging studies of ramosetron were previously conducted by Fujii et al., but all have
been retracted because of data fabrication [11,20,21]. Other studies investigating the effective dose of
ramosetron for PONV prophylaxis did not account for surgery- or patient-specific risks. For example,
one study investigated the effective dose of ramosetron in patients considered high-risk by Apfel’s
classification and reported that ramosetron 0.6 mg was more effective than ramosetron 0.3 mg in
reducing PONV during the 6 to 24 h postoperative period [9]. However, that study did not consider the
PONV risks associated with patient sex and type of surgery, as both men and women were included
and the type of surgery was not differentiated. Female sex is the strongest risk factor for PONV,
increasing the risk 2.57 times [4]. In addition, the number of patients in the study (15 or 16 patients per
group) was relatively small. These limitations might have contributed to the discrepancy between
that study’s results and our findings. Another study compared the efficacy of single-dose (at the
end of surgery) and two-dose (at the end of surgery and 4 h later) ramosetron for preventing PONV
in patients undergoing laparoscopic gynecologic surgery [10]. Two doses were not superior to one
dose. However, the type of anesthesia was not controlled in that study, and three different types were
used: propofol induction–volatile anesthetic maintenance, thiopental induction–volatile anesthetic
maintenance, and propofol induction–propofol maintenance. Volatile anesthetics are the strongest
anesthesia-related predictor and the leading cause of early postoperative vomiting [22,23], whereas
propofol reduces PONV, compared with volatile anesthetics [24,25]. In addition, non-opioid based
IV-PCA was used for postoperative analgesia in that study, so the risk of PONV may have been lower
than in our patients. Thus, the literature contains little reliable data regarding the optimal dose of
ramosetron for PONV prevention in high-risk patients. In the current study, most patients had three
(71%) or four (26%) Apfel risk factors, with corresponding estimated risks for PONV as high as 61%
or 79% [3]. In addition, laparoscopic gynecologic surgery and use of volatile anesthetic agents may
have further increased the risk of PONV [19]. Thus, in these highly susceptible patients, we found
that increasing the dose of ramosetron to 0.45 and 0.6 mg was not superior to ramosetron 0.3 mg for
reducing the incidence of PONV and severity of nausea during the first 48 h postoperatively.
Appropriate postoperative pain relief can facilitate early recovery and increase patient satisfaction.
Although opioid-based PCA is a safe and effective method of providing analgesia [26], it also increases
the incidence of PONV by up to 50% [27], resulting in early discontinuation of PCA and inadequate
pain control. Thus, it is important to identify an adequate regimen that not only reduces pain intensity
but also prevents PCA-related PONV. In the present study, higher doses of ramosetron were associated
with a reduced incidence of early discontinuation of PCA and increased patient satisfaction regarding
postoperative pain relief and PONV. The number of patients in whom IV-PCA was discontinued
because of intractable PONV despite rescue antiemetics was much lower in the R0.45 and R0.6 groups
than in the R0.3 group. This may have contributed to the higher patient satisfaction scores in the R0.45
and R0.6 groups. Of note, ramosetron 0.45 mg was as effective as 0.6 mg for patient satisfaction.
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Although ramosetron has fewer sedative, dystrophic, and extrapyramidal symptoms than
antiemetics such as droperidol and metoclopramide, the safety profile of higher ramosetron doses
must be considered. Previous studies have reported no differences in the incidence of adverse effects,
including dizziness, headache, and drowsiness, with increasing doses of ramosetron [9,10]. Consistent
with these findings, our results showed that ramosetron 0.45 mg and 0.6 mg were not associated with
increased adverse events compared to ramosetron 0.3 mg.
There are limitations to the present study. First, as we added ondansetron in the IV-PCA solution,
we could not exclude the potential impact of ondansetron on PONV. As the incidence of premature
discontinuation of IV-PCA containing ondansetron was higher in the R0.3 group, the infused dose
of ondansetron was less in the R0.3 group (8, (7.6, 8) mg) compared to the R0.45 (8 (8, 8) mg) and
R0.6 (8 (8, 8) mg) groups (p = 0.003). However, ramosetron has higher receptor binding capacity
and is more effective at reducing PONV than ondansetron [6,16]. When patients who had premature
discontinuation of IV-PCA were excluded, the incidence of PONV was not statistically different
between the three groups (p = 0.246). Second, the observed incidence of PONV in this study was
only half of what was assumed in sample size calculation. The higher incidence of PONV in the
previous study (70%) [13] might have been attributed to the use of nitrous oxide and younger patient
age. We performed multimodal prophylaxis to prevent PONV, including the absence of nitrous oxide,
which might have reduced the incidence of PONV. Therefore, there is a possibility that the sample
size might be insufficient to detect the assumed effect, with the chance of a type II error. However,
when we calculated the effect size using the differences in the PONV incidences between the groups,
the effect size was 0.06, which represents a trivial difference in the incidences.
In conclusion, higher doses of ramosetron (0.45 and 0.6 mg) did not reduce PONV in high-risk
patients undergoing laparoscopic gynecologic surgery. However, these higher doses reduced premature
discontinuation of IV-PCA caused by intractable PONV and increased patient satisfaction, without
increasing adverse events, when compared with ramosetron 0.3 mg. Therefore, ramosetron 0.45 mg
may be the most appropriate PONV prophylaxis dose for high-risk patients undergoing laparoscopic
gynecologic surgery and receiving postoperative opioid-based analgesia.
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